编者按：第54届国际实验血液学会年度科学会议（ISEH 2025）于9月24日至27日在日本熊本盛大召开。作为血液学领域的重要国际盛会，本次大会汇聚了全球顶尖专家，围绕基础血液学、免疫学、干细胞研究及细胞与基因治疗等前沿方向展开深度研讨，共探领域最新进展。会议期间，《肿瘤瞭望-血液时讯》特别邀请ISEH曾任主席、北京协和医学院特聘教授Toshio Suda教授，就本次大会的核心亮点及干细胞研究领域的前沿动态进行了深入解读。
《肿瘤瞭望-血液时讯》您曾任国际实验血液学会（ISEH）主席，如今再次见证大会在熊本召开，您如何评价本次大会的独特价值？
Toshio Suda教授：十年前，我曾担任ISEH主席。本次大会在日本熊本举行，因众多中国研究者的积极参与而彰显革新意义，中国参会者的数量在所有参会群体中位居首位，使此次大会具有非凡的纪念价值。众所周知，中国血液学处于国际领先水平，标志我们正步入血液学新时代。
Oncology Frontier-Hematology Frontier：You previously served as the President of the International Society for Experimental Hematology (ISEH), and now you are witnessing the conference being held in Kumamoto. How do you assess the unique value of this conference?
Prof. Toshio Suda：Ten years ago, I served as the President of ISEH. This conference, held in Kumamoto, Japan, is marked by significant innovation due to the active participation of numerous Chinese researchers, whose attendance ranked first among all participating groups, endowing the event with exceptional commemorative value. As is well known, Chinese hematology has reached an international leading level, signifying that we are entering a new era in the field of hematology.
《肿瘤瞭望-血液时讯》本次大会的亮点之一是“中日干细胞与细胞治疗联合研讨会”。您如何看待中日两国在血液学领域的学术交流与合作前景？
Toshio Suda教授：我们成功举办了“中日干细胞与细胞治疗联合研讨会”这一会前研讨会，在程涛教授与王建祥教授的大力支持下，取得圆满成效。早在40年前，两国之间曾有过十分紧密的学术交流，但此后出现中断，因此亟需重启并延续这段对话。
Oncology Frontier-Hematology Frontier：One of the highlights of this conference is the "China-Japan Stem Cell and Cell Therapy Joint Symposium." What is your view on the prospects for academic exchange and collaboration between China and Japan in the field of hematology?
Prof. Toshio Suda：We successfully held the pre-conference symposium titled "China-Japan Joint Workshop on Stem Cells and Cell Therapy," achieving outstanding results with the strong support of Professors Tao Cheng and Jianxiang Wang. As early as 40 years ago, the two countries maintained close academic exchanges, which were subsequently interrupted. Consequently, there is an urgent need to revive and continue this dialogue.
《肿瘤瞭望-血液时讯》在本次会议上，您分享了“造血干细胞的自我更新活性：从初生到衰老”的研究内容。您能否阐述这一研究对理解干细胞功能和临床应用的意义？
Toshio Suda教授：干细胞生物学作为支撑细胞治疗的重要基础学科，近年来在干细胞体外扩增及多种细胞治疗（如CAR-T疗法）方面展现出显著进展。将基础研究成果有效转化为临床应用，是推动该领域发展的关键，因此这一方向具有广阔而深远的前景。
Oncology Frontier-Hematology Frontier：In this conference, you shared your research on "Hematopoietic Stem Cell Self-Renewal Activity: From Birth to Aging." Could you elaborate on the significance of this research for understanding stem cell function and its potential clinical applications?
Prof. Toshio Suda：Stem cell biology, as a foundational discipline supporting cell therapy, has shown remarkable progress in recent years in areas such as in vitro stem cell expansion and various cell therapies, including CAR-T therapy. Effectively translating basic research findings into clinical applications is critical to advancing this field, offering broad and far-reaching prospects.
《肿瘤瞭望-血液时讯》：展望未来，您认为在造血干细胞研究或基础血液学领域中，哪些方向最具潜力？目前存在哪些关键科学或技术挑战，有望通过未来的研究得到突破？
Toshio Suda教授：干细胞的体外扩增、基因疗法及免疫疗法等领域近年来取得了显著进展，尽管预测这些领域的突破并非易事，因为杰出成果往往出乎意料地出现。目前，我们可以设想，体外扩增的干细胞可用于移植治疗血液病患者。然而，为持续推动这些先进疗法的发展，基础科学研究仍需坚持不懈地进行。
Oncology Frontier-Hematology Frontier：Looking ahead, what areas do you believe have the most potential in hematopoietic stem cell research or basic hematology? What are the key scientific or technical challenges that remain, and which breakthroughs do you anticipate may occur through future research?
Prof. Toshio Suda：Significant progress has been made in recent years in the fields of ex vivo stem cell expansion, gene therapy, and immunotherapy, although predicting breakthroughs in these areas is challenging, as outstanding results often emerge unexpectedly. At present, it can be envisaged that ex vivo expanded stem cells may be used for transplantation in patients with blood disorders. However, to sustain the advancement of these cutting-edge therapies, basic scientific research must be pursued persistently.
专家简介
Toshio Suda教授
北京协和医学院特聘教授
研究领域主要包括造血干细胞微环境调控，分子和代谢调控，以及造血干细胞衰老方面的研究。在造血干细胞调控领域深耕四十余年，曾任日本庆应义塾大学教授，新加坡国立大学癌症研究所高级首席研究员，熊本大学国际医学研究中心主任，获国家海外高层次人才、天津市“海河英才”等称号，并主持国家自然科学基金合作创新研究团队项目、中国医学科学院医学与健康科技创新工程等。
在Cell、Nature、Nat Med、Cell Stem Cell、Immunity、Blood、J Cli Invest、EMBO J、J Exp Med和PNAS等杂志上发表了超过500多篇同行评审论文，被引用超过5万多次。在众多国际顶级学术期刊如Blood、J Exp Med、Stem Cells担任编辑委员会委员，担任Cell Stem Cell的顾问委员，担任Blood Science编辑委员会委员。曾任国际实验血液学学会主席，现任其会刊Exp Hematology主编。